Alimta

Alimta

Alimta is used in the following cases:

Malignant pleural mesothelioma:

-      Alimta® in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer:

-      Alimta® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other

than predominantly squamous cell histology

-      Alimta® is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly

squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

-      Alimta® is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology

Alimta